Efgartigimod induced rapid functional improvement in four patients with autoimmune nodopathy, achieving complete remission in anti‐NF186 IgG3+ neuropathy and partial recovery in IgG4‐dominant paranodal subtypes (anti‐NF155/CNTN1+). Here, CNTN1 is linked to neuropathy.